Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naproxcinod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Nicox SA
Deal Size : Not Applicable
Deal Type : Not Applicable
Nicox Updates on Fera Pharmaceuticals’ Continuing Evaluation of Naproxcinod
Details : Naproxcinod, a Cyclooxygenase-Inhibiting Nitric Oxide (NO)-Donating (CINOD) naproxen, is a non-steroidal anti-inflammatory product candidate engineered to release NO and naproxen, originally discovered and developed by Nicox.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 30, 2021
Lead Product(s) : Naproxcinod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Nicox SA
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Naproxcinod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Nicox SA
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Naproxcinod is a nonsteroidal anti-inflammatory product candidate engineered to release NO and naproxen, originally discovered and developed by Nicox. Fera will evaluate naproxcinod as a potential adjuvant treatment for patients with COVID-19 infection.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2020
Lead Product(s) : Naproxcinod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Nicox SA
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?